CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net revenue	[1]	$ 15,880	$ 7,053
Cost of revenue		3,776	2,242
Gross profit		12,104	4,811
Operating expenses:
Research, development and clinical trials		7,534	4,532
Selling, general and administrative		13,939	6,786
Total operating expenses		21,473	11,318
Loss from operations		(9,369)	(6,507)
Other income (expense):
Interest expense		(960)	(952)
Other expense, net		(227)	(454)
Total other expense, net		(1,187)	(1,406)
Loss before income taxes		(10,556)	(7,913)
Provision for income taxes		(6)	(4)
Net loss		$ (10,562)	$ (7,917)
Net loss per share attributable to common stockholders, basic		$ (0.38)	$ (0.29)
Net loss per share attributable to common stockholders, diluted		$ (0.38)	$ (0.29)
Weighted average common shares outstanding, basic		27,950,330	27,368,090
Weighted average common shares outstanding, diluted		27,950,330	27,368,090

[1] Net revenue by country is categorized based on the location of the end customer.